Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.38 |
| ▸ | EIF4E | P06730 | 2/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | KIF5B | P33176 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7128562 | 0.85 | EGFR (0.44) | EGFRMKNK1MKNK2PDGFRBRET | |
| SCHEMBL7124663 | 0.84 | EGFR (0.41) | EGFRCSF1RMKNK1MKNK2EIF4E | |
| SCHEMBL7119444 | 0.83 | EGFR (0.54) | EGFRKDR | |
| SCHEMBL7121719 | 0.78 | EGFR (0.49) | EGFRCSF1R | |
| SCHEMBL7128164 | 0.76 | EGFR (0.55) | EGFRMKNK1MKNK2EIF4E | |
| SCHEMBL7128169 | 0.76 | EGFR (0.55) | EGFRMKNK1MKNK2EIF4E | |
| SCHEMBL7119061 | 0.76 | EGFR (0.43) | EGFRCSF1RPDGFRBGAA | |
| SCHEMBL7117602 | 0.75 | EGFR (0.54) | EGFRMKNK1MKNK2EIF4E | |
| SCHEMBL7117605 | 0.75 | EGFR (0.54) | EGFRMKNK1MKNK2EIF4E | |
| SCHEMBL7117634 | 0.74 | EGFR (0.43) | EGFRCSF1RPDGFRBRETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | claimed |
| US-6153617-A | Irreversible bicyclic inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY (US) | 2000-11-28 | — | — | US | claimed |
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | disclosed |
| US-6153617-A | Irreversible bicyclic inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY (US) | 2000-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885CSF1R 890/4885MKNK1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.